Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by HB Wealth Management LLC

HB Wealth Management LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,003 shares of the biopharmaceutical company’s stock after selling 126 shares during the period. HB Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,270,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Capital International Investors grew its position in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after buying an additional 1,390,534 shares in the last quarter. GAMMA Investing LLC raised its holdings in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after acquiring an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. Pacer Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock worth $258,366,000 after purchasing an additional 390,374 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock worth $305,311,000 after purchasing an additional 303,785 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 0.1%

Regeneron Pharmaceuticals stock opened at $558.15 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock has a market capitalization of $60.26 billion, a PE ratio of 14.21, a price-to-earnings-growth ratio of 2.10 and a beta of 0.33. The firm has a 50 day simple moving average of $540.67 and a 200-day simple moving average of $606.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the business posted $9.55 earnings per share. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.63%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $700.00 to $580.00 in a research report on Friday, May 30th. Guggenheim reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the company a “neutral” rating in a report on Friday, July 11th. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $755.00 to $754.00 and set an “overweight” rating on the stock in a research note on Thursday, July 10th. Finally, Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $837.61.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.